SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Trial details
- Registry ID
- NCT07187531
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesNCT07187531 | SABS | Phase 2 | Recruiting | 2027-11Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |